Form 4: Akero Director Converts Equity in Novo Nordisk Merger

Tomas J. Heyman, a director at Akero Therapeutics, Inc., disposed of all his common stock and stock options following the company's merger with Novo Nordisk A/S.

Summary

• Akero Therapeutics, Inc. (AKRO) merged with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S, effective December 9, 2025, with Akero surviving as a wholly-owned subsidiary of Novo Nordisk.
• Tomas J. Heyman, a director of Akero Therapeutics, disposed of 9,398 shares of common stock (restricted stock units) and 69,000 stock options as a result of the merger.
• Each restricted stock unit was converted into a right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) for an additional $6.00 in cash upon achievement of a specified milestone.
• Each compensatory stock option, whether vested or not, was converted into a cash payment equal to the excess of the $54.00 Closing Consideration over the option's exercise price, multiplied by the number of shares, plus one CVR per share.
• Following these transactions, Tomas J. Heyman beneficially owns 0 shares of common stock and 0 derivative securities of Akero Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person, as the merger resulted in a substantial cash payout for their equity holdings, along with potential additional value from the CVRs. The filing itself is factual and reports a completed corporate action.

Positives

• Reporting person received a significant cash payout of $54.00 per share for restricted stock units and the in-the-money value of stock options.
• The inclusion of a Contingent Value Right (CVR) for an additional $6.00 per share provides potential upside if a specified milestone is achieved.

Negatives

• Akero Therapeutics, Inc. ceases to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Novo Nordisk A/S.
• The $6.00 CVR payment is contingent on a future milestone, introducing uncertainty regarding the full potential consideration.

Risks

• The $6.00 per share contingent value right (CVR) is not guaranteed and is dependent on the achievement of a specified milestone, which may or may not occur.

Future Outlook

Akero Therapeutics, Inc. will operate as a wholly-owned subsidiary of Novo Nordisk A/S following the merger. The future outlook for the former Akero shareholders includes the potential realization of the CVR value based on milestone achievement.

Industry Context

This transaction represents a significant acquisition in the biotechnology sector, where larger pharmaceutical companies often acquire smaller, innovative firms to expand their pipeline or market presence. The structure of the deal, combining upfront cash with a contingent value right, is a common strategy in biotech M&A to share risk and reward related to pipeline assets.

Comparison to Industry Standards

• The use of a Contingent Value Right (CVR) in an acquisition is a common mechanism in the biotechnology and pharmaceutical industries, often seen in deals where the acquired company has promising drug candidates in development but with uncertain future outcomes. This structure allows the acquirer to mitigate risk while providing potential upside to the selling shareholders.
• Similar CVR structures have been observed in other biotech acquisitions, such as the acquisition of Reata Pharmaceuticals by Biogen, where Reata shareholders received an upfront payment plus a CVR tied to the net sales of Skyclarys.

Stakeholder Impact

• Shareholders of Akero Therapeutics received cash consideration and CVRs for their shares, concluding their investment in the independent company.
• Employees, including the reporting person, had their equity compensation converted according to the merger terms.

Next Steps

• Akero Therapeutics, Inc. will continue operations as a wholly-owned subsidiary of Novo Nordisk A/S.
• Monitoring for the achievement of the specified milestone that triggers the $6.00 CVR payment.

Key Dates

Keywords

Akero Therapeutics, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, RSU, CVR, Biotechnology